Core Viewpoint - Haikang's stock price has shown a continuous upward trend, reflecting positive market sentiment and potential investment opportunities in the pharmaceutical sector [1][2]. Company Overview - Haikang Pharmaceutical Group Co., Ltd. was established on August 26, 2005, and went public on January 17, 2012. The company is located in Zedang Town, Shannan City, Tibet [1]. - The main business activities include research and development, manufacturing, and sales of chemical drugs [1]. - Revenue composition is as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other supplementary income 0.86% [1]. Stock Performance - As of October 17, Haikang's stock price increased by 0.75% to 52.50 CNY per share, with a trading volume of 227 million CNY and a turnover rate of 0.89%. The total market capitalization is 58.796 billion CNY [1]. - The stock has risen for three consecutive days, with a cumulative increase of 6.49% during this period [1]. Fund Holdings - Southern Fund's Southern Medical Health Flexible Allocation Mixed A (000452) holds a significant position in Haikang, with 3.9138 million shares, unchanged from the previous period, accounting for 6.84% of the fund's net value [2]. - The fund has realized a floating profit of approximately 1.5264 million CNY today and 12.5241 million CNY during the three-day upward trend [2]. - The fund was established on January 23, 2014, with a current scale of 2.405 billion CNY and has achieved a year-to-date return of 45.86% [2].

分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年6月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2127.63万股，相比上期增加535.74万股。工银前沿医疗股票A（001717）位居第六 大流通股东，持股1510.01万股，相比上期增加540.00万股。汇添富创新医药混合A（006113）位居第七 大流通股东，持股1242.67万股，相比上期增加267.25万股。富国精准医疗灵活配置混合A（005176）位 居第八大流通股东，持股937.79万股，相比上期减少191.01万股。汇添富医疗服务灵活配置混合A （001417）位居第九大流通股东，持股875.93万股，相比上期减少170.31万股。香港中央结算有限公司 位居第十大流通股东，持股817.97万股，为新进股东。 责任编辑：小浪快报 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉 ...

10月15日，海思科涨5.03%，截至发稿，报51.78元/股，成交9643.00万元，换手率0.39%，总市值579.89 亿元。 中信建投医改A（002408）成立日期2016年4月6日，最新规模6.03亿。今年以来收益26.89%，同类排名 3036/8161；近一年收益15.85%，同类排名4467/8015；成立以来收益86.51%。 中信建投医改A（002408）基金经理为谢玮。 截至发稿，谢玮累计任职时间7年135天，现任基金资产总规模19.87亿元，任职期间最佳基金回报 90.48%， 任职期间最差基金回报-26.44%。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 从基金十大重仓股角度 数据显示，中信建投基金旗下1只基金重仓海思科。中信建投医改A（002 ...

10月13日，海思科盘中下跌2.05%，截至10:04，报50.55元/股，成交5466.47万元，换手率0.22%，总市 值566.12亿元。 资金流向方面，主力资金净流入205.01万元，大单买入759.77万元，占比13.90%，卖出554.76万元，占 比10.15%。 海思科今年以来股价涨53.27%，近5个交易日跌6.91%，近20日跌13.81%，近60日涨13.98%。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 海思科所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、高血压防 治、生物医药、创新药、互联医疗等。 截至6月30日，海思科股东户数1.14万，较上期增加25.93%；人均流通股42147股，较上期减少28.64%。 ...

Core Viewpoint - The stock of Haishike has shown significant performance with a year-to-date increase of 76.74%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 11, Haishike's stock price reached 58.29 CNY per share, with a market capitalization of 65.28 billion CNY [1]. - The stock has experienced a 1.78% increase over the last five trading days and a 37.93% increase over the last 60 days [1]. - The company has seen a net outflow of 4.30 million CNY in principal funds, with large orders showing a buy of 14.74 million CNY and a sell of 19.74 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.00 billion CNY, reflecting an 18.63% year-on-year growth, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. - Cumulatively, the company has distributed 3.67 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per person, down by 28.64% [2]. - The top ten circulating shareholders include several mutual funds, with notable increases in holdings from institutions such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3].